As it was observed that Musclin may be able to alleviate cancer-induced muscle wasting during cachexia, which is characterized by systemic inflammation through elevated levels of pro-inflammatory cytokines such as TNF-alpha, it might serve as a novel marker for cachexia development and potential therapeutic target. This evidence concerns the gene OSTN and Cachexia.